Leerink Boosts PT on Heron Therapeutics (HRTX) to $57 Following HTX-011 Phase 2 Top-Line Results
Tweet Send to a Friend
Leerink lifts its price target on Outperform-rated Heron Therapeutics (Nasdaq: HRTX) from $38 to $57 after the company announced positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
